Skip to main content

Table 2 Body size change and obesity-related cancer risk

From: Association of childhood-to-adulthood body size change with cancer risk: UK Biobank prospective cohort

 

Thinner → normal weight

Thinner → overweight

Thinner → obesity

Average → normal weight

Average → overweight

Average → obesity

Plumper → normal weight

Plumper → overweight

Plumper → obesity

All obesity-related cancers (N = 15,193)

  

No. cases

1746

2141

1240

2160

3276

2159

393

1878

1200

Incidence ratea

389.7

469.8

618.4

387,3

434.8

572.8

385.0

423.4

547.8

HR (95% CI)b

1.07 (1.00–1.14)

1.28 (1.21–1.36)

1.61 (1.50–1.73)

Reference

1.19 (1.12–1.26)

1.53 (1.44–1.63)

0.99 (0.89–1.10)

1.15 (1.06–1.24)

1.52 (1.41–1.63)

Obesity-related cancers, excluding breast cancer (N = 10,453)

      

No. cases

1076

1479

895

1311

2337

1554

255

629

917

Incidence ratea

237.7

321.1

440.5

232.5

307.3

407.4

247.2

300.5

414.5

HR (95% CI)b

1.04 (0.96–1.12)

1.24 (1.15–1.34)

1.66 (1.52–1.82)

Reference

1.21 (1.13–1.29)

1.58 (1.46–1.70)

1.12 (0.98–1.28)

1.26 (1.15–1.39)

1.76 (1.61–1.92)

Post-menopausal breast cancer (N = 5027)

  

No. cases

695

703

370

889

988

648

146

270

318

Incidence ratea

260.3

352.9

360.4

234.7

288.3

343.1

187.5

230.1

250.7

HR (95% CI)b

1.12 (1.02–1.24)

1.43 (1.29–1.58)

1.54 (1.36–1.75)

Reference

1.17 (1.07–1.28)

1.45 (1.31–1.61)

0.82 (0.69–0.98)

0.98 (0.86–1.13)

1.14 (1.00–1.29)

Colorectal cancer (N = 4052)

  

No. cases

462

626

304

536

936

545

96

226

294

Incidence ratea

101.5

135.0

148.0

94.5

125.7

141.5

92.5

107.3

131.5

HR (95% CI)b

1.07 (0.94–1.21)

1.21 (1.08–1.36)

1.37 (1.18–1.58)

Reference

1.14 (1.02–1.27)

1.31 (1.16–1.48)

1.07 (0.86–1.33)

1.09 (0.93–1.27)

1.38 (1.20–1.60)

Endometrial cancer (N = 986)

  

No. cases

84

103

110

96

169

204

28

46

146

Incidence ratea

31.0

50.6

105.1

25.0

48.5

106.2

35.6

38.7

114.0

HR (95% CI)b

1.26 (0.94–1.69)

1.95 (1.47–2.58)

4.13 (3.11–5.48)

Reference

1.86 (1.45–2.40)

4.10 (3.19–5.25)

1.49 (0.98–2.27)

1.57 (1.10–2.23)

4.65 (3.57–6.05)

Kidney cancer (N = 1043)

  

No. cases

109

87

24

254

140

62

163

113

91

Incidence ratea

19.1

19.0

23.0

33.0

30.0

29.3

42.1

54.8

40.5

HR (95% CI)b

0.94 (0.71–1.24)

1.18 (0.91–1.52)

2.11 (1.61–2.77)

Reference

1.33 (1.06–1.67)

1.67 (1.31–2.14)

1.37 (0.88–2.14)

1.34 (0.98–1.84)

1.81 (1.36–2.40)

Pancreatic cancer (N = 972)

  

No. cases

103

132

68

110

239

151

23

57

89

Incidence ratea

22.5

28.3

32.9

19.3

31.0

38.9

22.1

26.9

39.6

HR (95% CI)b

1.16 (0.89–1.52)

1.23 (0.95–1.59)

1.41 (1.04–1.93)

Reference

1.38 (1.10–1.74)

1.75 (1.36–2.26)

1.25 (0.80–1.97)

1.33 (0.96–1.83)

2.03 (1.53–2.70)

Esophagus (N = 747)

  

No. cases

64

108

58

81

189

115

51

58

60

Incidence ratea

14.0

23.1

28.1

14.2

24.5

29.7

20.1

14.1

26.7

HR (95% CI)b

0.94 (0.68–1.31)

1.19 (0.89–1.60)

1.45 (1.03–2.05)

Reference

1.29 (0.99–1.68)

1.58 (1.18–2.11)

1.67 (1.03–2.70)

1.50 (1.05–2.13)

1.69 (1.21–2.38)

  1. Abbreviations: CI confidence interval, CRC colorectal cancer, HR hazard ratio, HRT hormone replacement therapy, NSAIDs nonsteroidal anti-inflammatory drugs
  2. aIncidence rate per 100,000 person-years
  3. bModel adjusted for age, sex, ethnicity, height, Townsend deprivation index, education, smoking, alcohol consumption, red and processed meat consumption, 1st-degree family history of CRC and breast cancer, previous CRC screening (for obesity-related cancers and CRC), previous mammography (women only; for obesity-related cancers and breast cancer), HRT (women only), fruit and vegetable intake, NSAIDs use, and physical activity